$1.72
-33%Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.
Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation
Base year metrics used for projections
Forecast period and terminal assumptions
Calculation flow from present value to intrinsic value per share
Operating Cash Flow - Maintenance CapEx = Owner Earnings
| Metric | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | Year 6 | Year 7 | Year 8 | Year 9 | Year 10 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$7.7M | -$9.4M | -$11.4M | -$13.8M | -$16.8M | -$20.4M | -$24.8M | -$30.2M | -$36.7M | -$44.6M |
| Maintenance CapEx | -$1 | -$1 | -$1 | -$1 | -$2 | -$2 | -$2 | -$3 | -$3 | -$4 |
| Owner Earnings | -$7.7M | -$9.4M | -$11.4M | -$13.8M | -$16.8M | -$20.4M | -$24.8M | -$30.2M | -$36.7M | -$44.6M |
| Discount Factor | 0.926 | 0.857 | 0.794 | 0.735 | 0.681 | 0.630 | 0.583 | 0.540 | 0.500 | 0.463 |
| Present Value | -$7.1M | -$8.0M | -$9.0M | -$10.2M | -$11.5M | -$12.9M | -$14.5M | -$16.3M | -$18.4M | -$20.7M |
Continue your ANEB research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.